Parkinson'
Conditions
Interventions
To conduct PET examinations using the following tracers: 18F-SMBT-1
To examine the effects of the following tracers on 18F-SMBT-1 PET: rasagiline
To examine the effects of the following tracers on 18
Sponsors
Cyclotron and Radioisotope Center, Tohoku University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Parkinson's disease (PD) patients (non-smokers): (1) Informed consent by the participant or by the substitues (native Japanese) (2) Ages: basically 50 to 90 years old (3) Fulfilling the conditions of PD (4) No history of smoking at least 1 year before entry (5) Those who can tolerate PET examination of up to 90 mins Parkinson's disease (PD) patients (non-smokers and plan of MAO-B inhibitor treatment): (1) Informed consent by the participant or by the substitues (native Japanese) (2) Ages: basically 50 to 90 years old (3) Fulfilling the conditions of PD and having the plan of MAO-B inhibitor treatment (should be before starting the treatment) (4) No history of smoking at least 1 year before entry (5) Those who can tolerate PET examination of up to 90 mins Parkinson's disease (PD) patients (smokers): (1) Informed consent by the participant or by the substitues (native Japanese) (2) Ages: basically 50 to 90 years old (3) Fulfilling the conditions of PD (4) Habitual smokers or having history of smoking at least 7 days before the entry (5) Those who can tolerate PET examination of up to 90 mins Healthy controls (non-smokers): (1) Informed consent by the participant or by the substitues (native Japanese) (2) Ages: basically 50 to 90 years old (3) Habitual smoking or history of smoking within 7 days of PET examination (4) Those who can tolerate PET examination of up to 90 mins Healthy controls (non-smokers): (1) Informed consent by the participant or by the substitues (native Japanese) (2) Ages: basically 50 to 90 years old (3) Habitual smoking or history of smoking within 7 days of PET examination (4) Those who can tolerate PET examination of up to 90 mins Healthy controls (smokers): (1) Informed consent by the participant or by the substitues (native Japanese) (2) Ages: basically 50 to 90 years old (3) Habitual smoking or history of smoking within 7 days of PET examination (4) Those who can tolerate PET examination of up to 90 mins
Exclusion criteria
Exclusion criteria: (1) Administration of irreversible MAO-B inhibitors, Habitual smoking (within 1 year of entry) (2) Being in the period of pregnancy, possible pregnancy, breast feeding, within 28 days after child birth (3) Severe allergic reactions to drugs and foods (4) Psychiatric disorders, which may make the participation to this study difficult (5) Taboo conditions for MRI examinations (cardiac pacemaker, intracorpoporial metals, etc. to be checked with questionnaire in advance) (6) Systemic circulatory and metabolic disorders as well as organ dysfuctions, such as diabetes melitus, hypertension, endocrinolog ical disorders, congestive heart failure, angina petoris, severe renal dysfunctions with Ccr<30mL/min or under plasmapheresis) (7) Past history of malignant diseases within 1 year of entry (8) Any sociomedial conditions, which may make the participation to this study difficult
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUV ratio (SUVR) | — |
Countries
Japan
Contacts
Public ContactKotaro Hiraoka
Cyclotron and Radioisotope Center, Tohoku University Division of Cyclotron Nuclear Medicine
Outcome results
None listed